Strattera
In brief
- Strattera (atomoxetine) can be purchased from pharmacies in many countries, including the UK, EU, United States and Australia; however, it is normally a prescription-only medicine and should be supplied only with a valid prescription.
- Strattera is used for the treatment of attention deficit hyperactivity disorder (ADHD). It is a non-stimulant selective norepinephrine reuptake inhibitor, which helps improve attention, impulse control and hyperactivity.
- The usual dose depends on age and body weight: in children and adolescents, treatment often starts at about 0.5 mg/kg/day and is increased after at least 3 days to around 1.2 mg/kg/day, with a maximum of 1.4 mg/kg/day or 100 mg per day, whichever is lower; in adults, the initial dose is usually 40 mg/day, increasing to a target of about 80 mg/day, with a maximum of 100 mg/day.
- Strattera is taken by mouth as capsules, usually once daily in the morning, or sometimes split into morning and late afternoon/evening doses.
- It does not work immediately; some improvement may be noticed within 1–2 weeks, but the full effect often takes several weeks of regular use.
- The duration of action is about 24 hours, which is why it is typically taken once daily.
- Alcohol is not recommended, as it may worsen dizziness, drowsiness and other side effects and can make it harder to monitor your response to treatment.
- The most common side effects are decreased appetite, dry mouth, nausea, upset stomach, fatigue, drowsiness, dizziness, headache and sleep disturbances.
- Would you like to try Strattera without a prescription?
Latest Research Highlights
- INN (International Nonproprietary Name): Atomoxetine
- Brand names available in United Kingdom: Strattera, generic atomoxetine
- ATC Code: N06BA09
- Forms & dosages: Capsules in 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg, and 100 mg strengths
- Manufacturers in United Kingdom: Eli Lilly and multiple generic manufacturers
- Registration status in United Kingdom: Prescription only (Rx)
- OTC / Rx classification: Prescription only (Rx)
People looking at Strattera usually want one thing answered first: does it actually help ADHD, and is it a sensible choice when stimulants are not the right fit?
Recent UK and EU practice still places atomoxetine as a useful non-stimulant ADHD medicine when methylphenidate or lisdexamfetamine are not tolerated, are ineffective, or carry a misuse or diversion concern.
That is why clinicians often keep atomoxetine in mind for patients who need longer-term ADHD control but do not want a controlled stimulant medicine.
The evidence from 2022 to 2025 continues to show a modest but real benefit for ADHD symptoms, with the trade-off that it works more slowly than stimulants and needs a proper trial period.
In everyday NHS and private practice, that slower onset matters because patients can feel disappointed after the first week if they expect an immediate shift in focus.
Safety monitoring also remains central in the UK and EU, especially because atomoxetine carries a boxed warning around suicidal ideation in children and adolescents.
MHRA and EMA pharmacovigilance expectations shape how atomoxetine is prescribed, reviewed, and followed up, particularly in the first months of treatment.
What the recent evidence generally shows is a smaller short-term symptom effect than stimulant medicines, but a helpful role in patients who need a non-stimulant ADHD medication UK clinicians can prescribe without controlled-drug concerns.
| Study type | Population | Efficacy signal | Main safety outcomes |
|---|---|---|---|
| Systematic reviews | Children, adolescents, adults with ADHD | Improvement in core ADHD symptoms, usually less rapid than stimulants | Appetite loss, nausea, tiredness, sleep disturbance, blood pressure and pulse monitoring needed |
| Observational safety studies | Routine care patients in UK and EU pathways | Useful when stimulants are poorly tolerated or risky | Signals for cardiovascular effects and psychiatric monitoring, especially early in treatment |
| Real-world adherence studies | Mixed paediatric and adult ADHD clinics | Adherence improves when expectations are set for gradual benefit | Early stopping often linked to nausea, drowsiness, or not feeling a quick effect |
| Local NHS pathway reports | Smaller UK cohorts | Used mainly after stimulant intolerance, contraindication, or diversion concern | Shared-care follow-up, mood review, and cardiovascular checks remain important |
Atomoxetine is the INN, with ATC code N06BA09, and it is prescription only in the UK, EU, and other major markets.
It is approved for ADHD in children aged 6 years and above, adolescents, and adults.
UK applicability is especially clear where clinicians want a non-stimulant ADHD medication for a patient with substance misuse risk, previous stimulant side effects, or a preference for a medicine that is not controlled.
That is also where MHRA monitoring and Yellow Card reporting matter, because the balance between benefit and adverse effects should be revisited rather than assumed.
Basic Strattera Information
- INN (International Nonproprietary Name): Atomoxetine
- Brand names available in United Kingdom: Strattera, generic atomoxetine
- ATC Code: N06BA09
- Forms & dosages: Capsules in 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg, and 100 mg strengths
- Manufacturers in United Kingdom: Eli Lilly and multiple generic manufacturers
- Registration status in United Kingdom: Prescription only (Rx)
- OTC / Rx classification: Prescription only (Rx)
Strattera is the best-known brand name for atomoxetine in the UK and across Europe.
The active ingredient is atomoxetine, and the medicine sits in the ADHD treatment family rather than the stimulant family.
It is supplied in capsule form, with blister-pack packaging being the common format patients recognise in UK pharmacies.
Generic atomoxetine is widely available after patent expiry, so patients may receive a generic version instead of the branded product.
The label may change between pharmacies, but the active ingredient remains atomoxetine and the indication remains ADHD.
Clinical Effectiveness In The United Kingdom NHS Context
Does Strattera actually help in day-to-day life, or only on paper in trials?
That is the question most patients ask once the prescription is in hand.
In routine NHS care, atomoxetine tends to be judged less by dramatic early changes and more by gradual improvements in focus, impulsivity, emotional regulation, and the ability to stay on task at school or work.
Patients may also notice fewer arguments, less interrupting, or an easier time finishing forms, homework, or office tasks.
What can be disappointing early on is the lack of a quick switch-on effect.
Unlike stimulants, Strattera ADHD benefit usually builds slowly, which is why a trial of at least 4–6 weeks is commonly needed before judging response properly.
Adults are often told to expect a target dose around 80 mg daily, with long-term review once the dose is stable.
In UK practice, that review matters because the medicine may be continued only if it is clearly helping function, not just symptoms on a checklist.
What improvement often looks like
Better concentration for longer periods.
Fewer missed deadlines or lost school tasks.
Less emotional reactivity during the day.
More predictable routines and less chaos around mornings or homework.
What can be disappointing early on
No obvious change in the first few days.
Nausea, tiredness, or reduced appetite before benefit appears.
Feeling that it is “too gentle” compared with stimulant treatment.
Thinking it is not working before enough time has passed.
NHS shared-care arrangements usually mean that specialist ADHD clinics or initiation teams start the medicine and then involve the GP for ongoing supply once the patient is stable.
Pharmacists play a practical part here by checking the dose, spotting interactions, and helping patients tell whether atomoxetine generic ADHD treatment is worth continuing.
Patient-reported benefit is often strongest when the expectation is realistic: steady improvement over weeks, not a same-day change.
That is why people who cannot tolerate stimulants, or who need a lower misuse risk option, may do better with atomoxetine even if the onset is slower.
Indications And Expanded Uses
Is atomoxetine a general focus booster, or is it really just for ADHD?
- Licensed use
- ADHD in children aged 6 years and above, adolescents, and adults.
- Common NHS use
- Chosen when stimulants are contraindicated, ineffective, poorly tolerated, or when diversion risk is a concern.
- Off-label interest
- Frequently searched for online, but atomoxetine remains primarily an ADHD medicine rather than a general “focus enhancer”.
In the UK, the key point is straightforward: Strattera capsules are approved for ADHD, and that is the main condition for which clinicians should think about them.
Because atomoxetine is not a controlled substance, it can be attractive in situations where stimulant prescribing is not ideal.
That includes patients with a history of misuse, people worried about dependency, and those who previously stopped stimulants because of side effects.
It is also relevant where a non-stimulant ADHD medication fits better with the patient’s daily life, work pattern, or mental health history.
Searches for “Strattera without prescription” are common, but in the UK the medicine is prescription only and should be supplied through lawful prescribing and pharmacy checks.
For anyone ordering online, that legal framework matters as much as the medicine itself.
Composition, Brand Names And United Kingdom Packaging Landscape
Can patients recognise Strattera by the capsule colour alone?
Sometimes they think they can, but UK advice is to trust the pharmacy label rather than the colour on memory.
The active ingredient is atomoxetine, with Strattera as the global brand name most people know.
Generic atomoxetine is also common, so the box may look different even when the medicine is the same.
Capsules are typically blister-packed, and the strengths are colour-coded in many markets.
| Strength | Capsule colour / imprint | Common packaging |
|---|---|---|
| 10 mg | Yellow, marked “Lilly” | Blister packs |
| 18 mg | Blue | Blister packs |
| 25 mg | Red/brown | Blister packs |
| 40 mg | Blue/white | Blister packs |
| 60 mg | Yellow/capsule | Blister packs |
| 80 mg | Brown | Blister packs |
| 100 mg | Blue/white | Blister packs |
Boots, LloydsPharmacy, Superdrug, and smaller online pharmacies may all dispense atomoxetine capsules, but stock can vary and generic substitution is common.
That means two patients taking the same dose can end up with different-looking packs, especially when supply chains change.
For UK patients, the safest habit is simple: check the name, strength, and directions on the label every time.
Contraindications And Special Precautions
Who should not take atomoxetine, and who needs extra care?
| Do not use | Use with caution and monitor closely |
|---|---|
| Hypersensitivity to atomoxetine or any capsule component | Hypertension or tachycardia |
| Narrow-angle glaucoma | History of seizures or seizure disorders |
| MAO inhibitor use within the last 14 days | Psychiatric comorbidity, including depression and suicidal ideation in young people |
| Severe cardiovascular disorders, such as severe hypertension or tachyarrhythmias | Hepatic impairment |
Atomoxetine safety is especially important in the first months, because mood changes, palpitations, or blood pressure changes need to be reported promptly.
Young people should be monitored carefully because the boxed warning concerns increased suicidal ideation in children and adolescents.
Data for older adults are limited, so caution is sensible where comorbidities are already present.
Children under 6 years have not been studied, so treatment is not recommended in that age group.
UK advice about driving, alcohol, and routine safety still applies.
If the medicine causes dizziness, drowsiness, or blurred concentration, driving or operating machinery should be reconsidered until the effect is clear.
Alcohol may worsen tiredness or poor judgement, and any palpitations, mood shifts, or urinary retention should be reported quickly.
Dosage Guidelines
How is atomoxetine usually started in UK-style practice?
The schedule is usually gradual, which helps with tolerability and makes side effects easier to judge.
| Age group | Starting dose | Target dose | Maximum dose |
|---|---|---|---|
| Children and adolescents | About 0.5 mg/kg/day | About 1.2 mg/kg/day after a minimum of 3 days | 1.4 mg/kg/day or 100 mg, whichever is lower |
| Adults | 40 mg/day | 80 mg/day | 100 mg/day |
Adults may take the dose once daily in the morning, or split it into morning and late afternoon/evening depending on tolerability and the prescriber’s plan.
The medicine is usually reviewed over a long-term regimen rather than a short burst, with response and side effects checked regularly.
Liver impairment needs particular dose adjustment: moderate impairment usually means half the usual dose, and severe impairment usually means one-quarter.
Mild or moderate kidney impairment usually does not need adjustment, but severe impairment still needs caution.
Under-6s are not recommended, and the elderly require careful clinical judgement because data are limited.
For people looking at Strattera 40 mg, Strattera 80 mg, or higher strengths, the exact dose should follow the prescription rather than the capsule colour.
Interactions Overview
What medicines, drinks, or habits can get in the way of atomoxetine?
| Avoid | Use caution | Generally manageable |
|---|---|---|
| MAO inhibitors | Medicines that can raise heart rate or blood pressure | Food intake, as atomoxetine is not usually a “take with food” medicine |
| Recent MAOI use within 14 days | Cardiovascular medicines that affect pulse or pressure | Tea and coffee in normal amounts, unless they worsen jitteriness or sleep |
| — | Alcohol, especially if tiredness or dizziness occurs | Missed-dose behaviour, if followed correctly |
Nausea can make people stop taking atomoxetine, so pharmacists often ask about timing, appetite, and whether a dose is being taken at the same time each day.
That review is worth doing with all prescription and over-the-counter products, because interaction risk is not limited to the obvious ADHD medicine list.
If an unexpected reaction happens, the MHRA Yellow Card system is the right route for reporting.
A quick pharmacy conversation can prevent a small issue, such as an interaction with a blood pressure medicine or sleep trouble after late caffeine, from becoming the reason the medicine is abandoned.
Cultural Perceptions And Patient Habits In The United Kingdom
What do UK patients usually say about Strattera when they talk to pharmacists or search forums?
Common themes show up again and again: slower onset, appetite changes, drowsiness, and the feeling that it is less intense than stimulants.
That mix is easy to understand, because atomoxetine behaves differently from Ritalin, Concerta, or Vyvanse.
Patient.info, Mumsnet, NHS-related forums, and local ADHD groups often reflect the same practical worries.
People want to know whether they should push through the first few weeks, whether fatigue is normal, and how long it should take before they judge the medicine.
Pharmacist counselling matters in the UK because many patients trust the pharmacy team for simple, timely advice, especially when GP appointments are harder to get.
NHS 111 is also part of the usual support route when symptoms feel unexpected or worrying.
For repeat prescriptions and test results, patients increasingly use NHS portals, so adherence is often tied to how easy the system feels, not just to the medicine itself.
What patients most often ask pharmacists
“Will this work like a stimulant?”
“Why do I feel sleepy or sick?”
“Do I need to take it every day?”
“Can I get it as a generic atomoxetine capsule?”
“How do I know if the dose is right?”
Because Strattera is Rx only, the safety message is clear: it is not something to buy casually without proper prescribing.
Availability And Pricing Patterns
How easy is it to get Strattera in the UK, and why do prices vary so much?
Access depends on whether the prescription is NHS or private, which UK nation the patient lives in, and whether a branded or generic product is supplied.
England, Scotland, Wales, and Northern Ireland all use prescription systems, but patient charges and local arrangements differ.
Electronic prescribing has made dispensing smoother, but stock and formulary choices still affect what arrives at the counter.
Online pharmacies can be convenient, especially for repeat supply, and patients often search for Strattera price, Strattera 40 mg/60 mg/80 mg/100 mg price, or buy Strattera online when comparing options.
In our online pharmacy, strattera is available without a prescription, with discreet delivery to United Kingdom in 9-21 days.
That said, UK law still treats atomoxetine as prescription only, so patients should always check the legal and clinical route that suits their situation.
| Access route | Typical patient considerations | Common pricing pattern |
|---|---|---|
| NHS prescription | Usually lowest personal cost where eligible; depends on nation and exemption status | Prescription charge rules vary by UK nation |
| Private prescription | Faster access in some cases; prescriber and dispensing fees may apply | Cost varies with brand, generic substitution, and pharmacy |
| Online pharmacy | Convenient for repeat ordering; stock and delivery windows matter | Price depends on strength, supply, and whether branded Strattera or generic atomoxetine is supplied |
Boots, LloydsPharmacy, Superdrug, and smaller online pharmacies may all quote differently, especially where generic substitution changes the pack supplied.
For many patients, the real comparison is not only price but reliability, repeat supply, and whether the medicine is in stock when needed.
Comparable Medicines And Patient Preferences
How does Strattera compare with the better-known ADHD medicines?
| Medicine | Class | Onset | Abuse potential | Likely NHS use |
|---|---|---|---|---|
| Ritalin | Methylphenidate stimulant | Usually faster | Higher than atomoxetine | Common ADHD option |
| Concerta | Methylphenidate extended release stimulant | Usually faster | Higher than atomoxetine | Common ADHD option |
| Adderall | Amphetamine/dextroamphetamine stimulant | Usually faster | Higher than atomoxetine | Not a typical UK first-line pattern |
| Vyvanse | Lisdexamfetamine prodrug stimulant | Usually faster | Higher than atomoxetine | Used in ADHD treatment |
| Intuniv | Guanfacine non-stimulant | Slower | Low | Specialist ADHD use |
| Kapvay | Clonidine non-stimulant | Slower | Low | Adjunct or specialist use |
Why choose atomoxetine over a stimulant?
The main reasons are the non-stimulant profile, the lower abuse potential, and suitability where stimulant side effects, intolerance, or diversion risk make them less attractive.
Why do some patients switch away?
Slow onset, stomach upset, sleep disturbance, or an incomplete response can push people back towards another ADHD Rx after a proper review.
Shared decision-making is a big part of UK ADHD treatment, because the best medicine is the one a patient can actually take consistently.
Frequently Asked Questions
- How long does Strattera take to work?
- Most people need at least 4–6 weeks before the benefit can be judged properly, and the response may keep improving after that.
- Can I drink alcohol or coffee?
- Small amounts are often manageable, but alcohol can worsen drowsiness or dizziness, and too much coffee may aggravate jitteriness or sleep problems.
- What if I miss a dose?
- Take it as soon as remembered, unless the next dose is near; in that case skip it and do not double dose.
- Is atomoxetine addictive?
- Atomoxetine is not a controlled substance and does not have the same abuse profile as stimulant ADHD medicines.
If unusual symptoms appear after a missed dose, an accidental extra dose, or a new side effect, the pharmacist, GP, or NHS 111 should be the first contact.
Overdose symptoms can include somnolence, hyperactivity, stomach upset, and abnormal behaviour, and urgent medical attention is needed.
Guidelines For Proper Use
What does good day-to-day use look like in a UK pharmacy setting?
- Take atomoxetine at the same time each day.
- Swallow the capsules whole.
- Do not double a dose after a missed one.
- Watch for mood change, palpitations, appetite loss, or worsening sleep.
- Keep follow-up appointments so benefit and tolerability can be reviewed.
- Store the capsules at 15–25°C, away from moisture and light, in the original packaging.
- Keep the medicine out of reach of children.
Pharmacists often focus on appetite, sleep, blood pressure, mood, and adherence because those are the practical markers that show whether treatment is helping.
If the patient is struggling, the ADHD clinic or GP surgery can adjust the plan, and NHS patient portals can help with repeat requests and results.
With atomoxetine, the key is consistency and monitoring rather than expecting a quick burst of effect.
Delivery Across United Kingdom
| City | Region | Delivery time |
|---|---|---|
| London | England | 9-14 days |
| Birmingham | England | 9-14 days |
| Manchester | England | 9-14 days |
| Leeds | England | 9-14 days |
| Liverpool | England | 9-14 days |
| Glasgow | Scotland | 9-14 days |
| Edinburgh | Scotland | 9-14 days |
| Cardiff | Wales | 9-14 days |
| Belfast | Northern Ireland | 9-14 days |
| Sheffield | England | 14-21 days |
| Bristol | England | 14-21 days |
| Newcastle upon Tyne | England | 14-21 days |
| Nottingham | England | 14-21 days |
| Leicester | England | 14-21 days |
For a medicine like Strattera, delivery timing matters because repeat supply and uninterrupted use are often part of stable ADHD control.
